AIDS vaccine not as effective as first idea.

Open Congress has a overview of the bill. This article is normally republished with kind authorization from our friends at The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Plan Record, search the archives, or sign up for email delivery of in-depth coverage of wellness policy developments, debates and discussions. The Daily Health Plan Report is released for Kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Board Business and Kaiser Family Basis. All rights reserved.. AIDS vaccine not as effective as first idea, scientists say A vaccine to protect against HIV may not be as effective as first thought, tuesday scientists said. The Wall Street Journal: ‘When 1st publicly disclosing the results of the vaccine trial in September, researchers said the vaccine experienced lowered the chance of illness by about 31 percent.Copyright 2009 Advisory Board Organization and Kaiser Family Base. All rights reserved.. AbbVie releases preliminary outcomes from ABT-414 Stage I study in individuals with recurrent or unresectable GBM AbbVie released preliminary results from an ongoing Phase I research with ABT-414, an anti-epidermal growth aspect receptor monoclonal antibody medication conjugate, in conjunction with temozolomide, which showed four objective responses, including a single complete response, in individuals with unresectable or recurrent glioblastoma multiforme. Specifically, one patient experienced a total response and three patients experienced partial responses as measured with the Revised Assessment in Neuro-Oncology criteria. ‘Glioblastoma multiforme is the most common and most aggressive kind of malignant primary brain tumor, and sufferers have few treatment plans and a five-year survival rate of significantly less than 3 %,’ said Gary Gordon, M.D.